Over a 3-year period, we monitored the efficacy and safety of deep-brain stimulation of the globus pallidus pars interna in patients with advanced Parkinson's disease whose cognitive, psychiatric impairment and/or dopa-resistant axial motor signs made them ineligible for surgery targeting the subthalamic nucleus.
The optimal target is still debated, some studies seems to show a superiority of the subthalamic nucleus (STN) over the globus pallidus pars interna (GPi), [5, 7] but some don't. [8, 10] However, STN DBS has been shown to carry a risk of disabling side effects, including cognitive decline, [11, 12] limbic effect [13] and the worsening of dopa-resistant axial motor signs. [14] In the light of these side effects, we can now identify patients who should not undergo subthalamic surgery. [15] As GPi DBS appears to entail less cognitive deterioration and fewer axial signs, [16] several centers have started offering this treatment to patients contraindicated to STN DBS. Its efficacy and safety have already been studied at 6 months post-surgery [17] in one such group of patients, with a motor benefit, no worsening of axial symptoms and no cognitive impairment. In the present study, we monitored its efficacy and safety in patients receiving bilateral pallidal stimulation over a 3-year period. All these patients had advanced PD refractory to all the usual medical treatments, with contraindications to STN DBS. At 3 years, one patient could not be assessed at all, owing to an advanced dementia syndrome, and two patients did not undergo the neuropsychological tests due to cognitive impairment.
MATERIAL AND METHODS

Patients
Surgical procedure
Quadripolar DBS electrodes (Medtronic, Minneapolis, MN) were implanted bilaterally in the posteroventral part of the GPi under general anesthesia in a single operating session. All dopaminergic medication had been withdrawn the day before, and patients were briefly woken during the procedure to test the clinical effect of stimulation on rigidity. The ventral contact was kept above the optical tract, as evidenced by the induction of visual flashes by stimulation. There was no Intraoperative microelectrode recording during the procedure.
The pulse generators (Soletra, Medtronic) were implanted 2-3 days later. The exact location of the two selected electrode contacts (one on the left and one on the right) was determined using stereotactic coordinates derived from a 3D CT scan performed a few days after surgery. The stimulation parameters were set and adjusted during appointments with the consultant and regular follow-up hospitalizations, based solely on clinical efficacy criteria.
Assessments
The patients were assessed before surgery (baseline), 1 year (M12) and 3 years (Y3) after surgery.
The clinical assessment included the UPDRS parts I (mental, behavior and mood), II (activities of daily Daily dopaminergic treatment was defined as the L-dopa equivalent dose (LED), calculated using method of Deuschl et al. [21] A global self-perceived Improvement was measured with a single-item Visual Analog Scale (VAS-I) ranging from 0% (no change) to 100% (best improvement). [22] The question was worded: "compared to the time before your operation, how would you judge your global improvement at the moment?"
Statistical analysis
We compared the different variables using the Wilcoxon signed-rank test, with the significance threshold set at p = 0.05. All the data are shown as means ± standard deviation (SD 
RESULTS
Motor results
The VAS-I score was 64 ± 23.9% at M12, and remained unchanged at Y3 (65.9 ± 15.6%; p = 1).
When the patients were stimulated (on stim), but without their dopaminergic medication (off dopa), there was a significant 19.8% improvement in the total motor score of the UPDRS-III at M12 (p = 0.04), which was maintained at Y3, with an improvement of 20.6% compared with baseline (p = 0.04) ( Table 2 ). An improvement in the Tremor subscore tended toward significance. We did not find any change in the Axial, Akinesia or Speech subscores, which remained stable at M12 and Y3. The UPDRS-II, the H&Y and the S&E scores measuring activities of daily living also remained stable at M12 and Y3.
In the on-stim/on-dopa conditions, patients' total motor score was stable at M12 (p = 0.13) and
remained so at Y3 (p = 0.27) ( Table 3 ). The Akinesia, Tremor and Axial subscores were also stable, with no significant deterioration at either M12 or Y3. There was, however, a significant worsening of the Speech subscore by M12 (p = 0.002). This was still present at Y3, but there had been no further
There was a significant deterioration in the UPDRS-II score at Y3 compared with baseline (p=0.002). The S&E and H&Y scores remained unchanged.
Motor complications of medical therapy
There was an improvement of 28.5% (p = 0.009) of the UPDRS-IV at M12 and 33% at Y3 (p = 0.02) compared with baseline (Table 3) , especially for the Dyskinesias subscore, which improved by 50% at M12 (p = 0.009) and 52% at Y3 (p = 0.007) ( Table 3) . No significant improvement in the Motor Fluctuations subscore was found.
Cognitive and neuropsychological results
At M12, all the cognitive and psychiatric abilities, as assessed with the UPDRS-I and the neuropsychological tests, did not change. By contrast, at Y3, we found significant deteriorations in the MDRS score (p = 0.049), the Stroop color-word (p = 0.01) and interference (p= 0.01) scores, and the TMT B-A (p = 0.01) score (Table 4 ). There was also a trend toward a worsening of the UPDRS-I score. Semantic and phonemic verbal fluency remained stable, as did WCST scores.
Quality-of-life scales
The SF-36 QoL score showed a trend toward deterioration between baseline and Y3 (48.8 ± 18 vs.
41.1 ± 14.7; p = 0.06), whereas the PDQ-39 scale remained stable over this period (38.21 ± 9 vs. 39.5 ± 11.8; p = 0.83).
Safety
One patient's electrode malfunctioned by Y3, following a fall with minor concussion, and one patient had to have an electrode removed at 2 years, after developing an infection (which responded favorably to treatment) without replacement. None of the patients died during follow-up.
Stimulation parameters and dopaminergic medication
The stimulation parameters (mean ± SD) at Y3 for the 25 patients were 2.96 ± 0.36 V, with a pulse width of 84.1 ± 21.6 μs and a frequency of 133.5 ± 14.9 Hz. At Y3, nine patients were stimulated using two contacts on each side, two patients were unilaterally stimulated via two contacts, while 14 patients
were bilaterally stimulated via one contact on each side. None of the patients needed to have their neurostimulator changed during the 3 years of the study. The stimulation did not bring about any reduction in the LED, which was 1263 ± 513 mg at baseline, 1431 ± 438 mg at M12, and 1375 ± 617 mg at Y3.
DISCUSSION
For patients with advanced Parkinson's disease refractory to medical treatment, the existence of doparesistant axial motor signs or cognitive impairment, leads to contraindication for surgical option. We
believe that these contraindications are specific to STN DBS and cannot be applied to GPI DBS, because pallidal surgery appears to entail less cognitive deterioration and fewer axial signs. [16, 17] Our results shows a motor benefits in the off-dopa condition that is still present 3 years after surgery, corresponding to the effect of the stimulation without any medication. In the on-dopa condition, we did not find any modification in the total motor score and no worsening of the Motor Fluctuations subscore, despite the expected disease progression, the motor benefit could be interpreted as low, but cannot be compared to the benefits in other studies on GPI DBS, because our patients due to the advanced PD and dopa resistant symptoms are systematically contraindicated for surgery in those studies.
We also find a major antidyskinetic effect, with a reduction at Y3 of more than 50% in the baseline Dyskinesias score, even though there was no postoperative reduction in dopaminergic medication.
This result confirms the specific antidyskinetic effect of the pallidal target, an effect that was maintained over time. The major reduction on dyskinesias is constantly found in the published data on GPI DBS, confirming the interest of this target on dyskinesias. [23, 24] We confirm the tolerance of this target with no worsening of dopa-resistant axial motor signs present prior to surgery, even though the patients selected were an at-risk population. This suggest that the stimulation had no adverse effect on axial signs at M12 and Y3, in contrast to previous reports. [25] Although there have been suggestions that GPi DBS leads to a worsening of akinetic symptoms, we did not observe any deterioration in the Akinesia subscore during the 3-year follow-up period. We did not evaluated adverse effects such as fatigue, apathy, mobility/falls and ICD and it will be useful to evaluate them with specific scales in further studies.
Dysarthria however was the only symptom that significantly worsened, with an early decline in the first
year, but none thereafter. This early deterioration suggest that it was an effect of the surgery, rather than of disease progression. We therefore believe it is important to make this particular risk known and take it into account when discussing the risks and benefits with patients who are potentially suitable for GPi surgery.
On cognitive assessments, at M12, the neuropsychological parameters remained unchanged, without early worsening, attributed to the stimulation, such as has been reported in some studies of STN There was a major self-estimated global clinical improvement of 65% still present at 3 years after the surgery. By contrast, there was no improvement in QoL and even a worsening of the UPDRS II at 3 years. We think that this discrepancy can be explained by the scales we used to measure this variable, as they are not particularly sensitive to change. We could also incriminate the cognitive 
CONCLUSION
GPi DBS in patients deemed ineligible for STN stimulation, owing to cognitive impairment or doparesistant axial signs, effectively reduces motor symptoms, and the benefits last at least 3 years.
Pallidal stimulation also considerably lessens treatment-induced motor complications, especially dyskinesias. It did not bring about any increase in akinesia, and had no adverse impact on axial signs and neuropsychological parameters. By contrast, there was a significant deterioration in speech, which will need to be taken into account when deciding on the most appropriate course of action. These results suggest that GPi DBS is a viable treatment for advanced idiopathic PD in patients ineligible for STN DBS, especially if they have acute dyskinetic complications, but those results are far from being definitive and should be assessed in further prospective studies.
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